These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 15069399

  • 1. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Muta H, Ishii M, Egami K, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T.
    J Pediatr; 2004 Apr; 144(4):496-9. PubMed ID: 15069399
    [Abstract] [Full Text] [Related]

  • 2. Use of intravenous gamma-globulin for Kawasaki disease: effects on cardiac sequelae.
    Yanagawa H, Nakamura Y, Sakata K, Yashiro M.
    Pediatr Cardiol; 1997 Apr; 18(1):19-23. PubMed ID: 8960487
    [Abstract] [Full Text] [Related]

  • 3. Cardiac sequelae of Kawasaki disease in Japan: statistical analysis.
    Nakamura Y, Fujita Y, Nagai M, Yanagawa H, Imada Y, Okawa S, Kawasaki T, Kato H.
    Pediatrics; 1991 Dec; 88(6):1144-7. PubMed ID: 1720235
    [Abstract] [Full Text] [Related]

  • 4. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.
    Muta H, Ishii M, Furui J, Nakamura Y, Matsuishi T.
    Acta Paediatr; 2006 Feb; 95(2):189-93. PubMed ID: 16449025
    [Abstract] [Full Text] [Related]

  • 5. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease.
    Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S.
    J Pediatr; 2000 Aug; 137(2):177-80. PubMed ID: 10931408
    [Abstract] [Full Text] [Related]

  • 6. Prognostic impact of vascular leakage in acute Kawasaki disease.
    Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y.
    Circulation; 2003 Jul 22; 108(3):325-30. PubMed ID: 12835221
    [Abstract] [Full Text] [Related]

  • 7. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 22; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 8. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan.
    Wanitkun S.
    J Pediatr; 2005 Jan 22; 146(1):149-50; author reply 150-1. PubMed ID: 15644851
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 22; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 10. Iv gamma globulin treatment of Kawasaki disease in Japan: results of a nationwide survey.
    Yanagawa H, Yashiro M, Nakamura Y, Sakata K, Kawasaki T.
    Acta Paediatr; 1995 Jul 22; 84(7):765-8. PubMed ID: 7549294
    [Abstract] [Full Text] [Related]

  • 11. Nationwide survey on Kawasaki disease in Japan.
    Yanagawa H, Kawasaki T, Shigematsu I.
    Pediatrics; 1987 Jul 22; 80(1):58-62. PubMed ID: 3601519
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome.
    Hsu CH, Chen MR, Hwang FY, Kao HA, Hung HY, Hsu CH.
    Pediatr Infect Dis J; 1993 Jun 22; 12(6):509-12. PubMed ID: 8345983
    [Abstract] [Full Text] [Related]

  • 13. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.
    Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H.
    Arch Dis Child; 2004 Aug 22; 89(8):776-80. PubMed ID: 15269082
    [Abstract] [Full Text] [Related]

  • 14. Clinical features of patients with Kawasaki disease whose parents had the same disease.
    Uehara R, Yashiro M, Nakamura Y, Yanagawa H.
    Arch Pediatr Adolesc Med; 2004 Dec 22; 158(12):1166-9. PubMed ID: 15583102
    [Abstract] [Full Text] [Related]

  • 15. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.
    Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T.
    J Pediatr; 2006 Aug 22; 149(2):237-40. PubMed ID: 16887442
    [Abstract] [Full Text] [Related]

  • 16. Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
    Sato N, Sugimura T, Akagi T, Yamakawa R, Hashino K, Eto G, Iemura M, Ishii M, Kato H.
    Pediatr Int; 1999 Feb 22; 41(1):1-7. PubMed ID: 10200128
    [Abstract] [Full Text] [Related]

  • 17. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
    Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K.
    Eur J Pediatr; 1994 Sep 22; 153(9):663-7. PubMed ID: 7957426
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug 22; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

  • 19. Cardiac sequelae of Kawasaki disease in Japan over 10 years.
    Hirose K, Nakamura Y, Yanagawa H.
    Acta Paediatr Jpn; 1995 Dec 22; 37(6):667-71. PubMed ID: 8775548
    [Abstract] [Full Text] [Related]

  • 20. Kawasaki disease. Kawasaki disease?
    Moss KW.
    Alaska Med; 2000 Dec 22; 42(2):30-6. PubMed ID: 10916855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.